title: [Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation].
abstract: One hundred and eleven patients receiving conditioning regimens for hematopoietic stem cell transplantation (HSCT) were administered a single intravenous dose (40 micrograms/kg) of granisetron before chemo-radio therapy. The efficacy of the drug was assessed every 24 hours, rating the control of nausea and vomiting as complete, major, minor or failure. On day 1, 23 of 48 patients (47.9%) who received cyclophosphamide (60 mg/kg/day), achieved control of emesis with complete or major response. On day 2, 17 of 47 patients (36.2%) achieved control emesis. During total body irradiation (TBI) (10 approximately 12 Gy/2 approximately 3 days), 21 of 33 patients (63.6%) achieved control of emesis on day 1 and 22 of 32 patients (68.6%) achieved control of emesis on day 2. During melphalan administration (60 approximately 100 mg/m2/day), 20 of 28 patients (71.4%) achieved control of emesis on day 1. Adverse effects were observed in seven patients but were not serious. We concluded that granisetron has a major role in preparation for HSCT.
authors.forename: N
authors.initials: N
authors.lastname: Hirabayashi
authors.forename: S
authors.initials: S
authors.lastname: Goto
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
authors.forename: H
authors.initials: H
authors.lastname: Sao
authors.forename: T
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Y
authors.initials: Y
authors.lastname: Kodera
authors.forename: H
authors.initials: H
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Horibe
authors.forename: K
authors.initials: K
authors.lastname: Yano
authors.forename: H
authors.initials: H
authors.lastname: Kojima
authors.forename: M
authors.initials: M
authors.lastname: Ogura
authors.forename: M
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
authors.forename: M
authors.initials: M
authors.lastname: Yazaki
authors.forename: M
authors.initials: M
authors.lastname: Utsumi
authors.forename: K
authors.initials: K
authors.lastname: Nagata
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: T
authors.initials: T
authors.lastname: Naoe
authors.forename: H
authors.initials: H
authors.lastname: Saito
mesh_terms: D000293:Adolescent; D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D002066:Busulfan / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007223:Infant; D008297:Male; D008558:Melphalan / Q000009:adverse effects; D008875:Middle Aged; D009325:Nausea / Q000209:etiology / Q000517:prevention & control*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D019172:Transplantation Conditioning; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*; D014916:Whole-Body Irradiation / Q000009:adverse effects
chemical_list: D000932:Antiemetics; D002066:Busulfan; D003520:Cyclophosphamide; D017829:Granisetron; D007166:Immunosuppressive Agents; D008558:Melphalan; D012702:Serotonin Antagonists